Clinical study "common" name (formal title)	Number of enrollees (per protocol [PP]/intent-to-treat [ITT])	Funding source (pharmaceutical company/National Institutes of Health [NIH])	Year completed	Primary publication	Full study treatment protocol
REPAIR (Ranibizumab in Myopic Choroidal Neovascularization: The 12-Month Results From the REPAIR Study)	N=65	Novartis (NCT01037348)	41030	Tufail A, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120(9):1944-1945. https://www.aaojournal.org/article/S0161-6420(13)00501-0/fulltext